Literature DB >> 20824446

Clinical trials and rare diseases.

Joachim Werner Otto Gerss1, Wolfgang Köpcke.   

Abstract

Whenever possible, standard methodological approaches should be applied in the design and analysis of a clinical trial that warrant adequate informative value. However, there are circumstances when the number of experimental subjects is unavoidably small. In such circumstances it is justified to consider abandoning standard statistical methodology in place of alternative approaches. Performing a small clinical trial however it should be pointed out, that a such trial can never be as meaningful and provide as much evidence as a larger trial. In the present text, basic concepts are presented, that apply to small clinical trials in general. Moreover, several specific methodological approaches are presented, that either enhance the efficiency of standard statistical procedures or evolve from the idea of abandoning classical paradigms in the design and analysis of clinical trials. Within the scope of the former approach, (Bayesian) adaptive randomisation, group sequential (adaptive) designs, repeated measurement designs for longitudinal data, and meta-analyses are illustrated and discussed. The latter approach comprises alternative strategies such as (non-randomised) risk-based allocation designs, statistical prediction designs, ranking and selection designs, as well as the application of Bayesian statistics.

Mesh:

Year:  2010        PMID: 20824446     DOI: 10.1007/978-90-481-9485-8_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  11 in total

1.  The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?

Authors:  Elizabeth O Lillie; Bradley Patay; Joel Diamant; Brian Issell; Eric J Topol; Nicholas J Schork
Journal:  Per Med       Date:  2011-03       Impact factor: 2.512

Review 2.  Treatable inherited rare movement disorders.

Authors:  H A Jinnah; Alberto Albanese; Kailash P Bhatia; Francisco Cardoso; Gustavo Da Prat; Tom J de Koning; Alberto J Espay; Victor Fung; Pedro J Garcia-Ruiz; Oscar Gershanik; Joseph Jankovic; Ryuji Kaji; Katya Kotschet; Connie Marras; Janis M Miyasaki; Francesca Morgante; Alexander Munchau; Pramod Kumar Pal; Maria C Rodriguez Oroz; Mayela Rodríguez-Violante; Ludger Schöls; Maria Stamelou; Marina Tijssen; Claudia Uribe Roca; Andres de la Cerda; Emilia M Gatto
Journal:  Mov Disord       Date:  2017-09-01       Impact factor: 10.338

Review 3.  Trial Design Challenges and Approaches for Precision Oncology in Rare Tumors: Experiences of the Children's Oncology Group.

Authors:  Lindsay A Renfro; Lingyun Ji; Jin Piao; Arzu Onar-Thomas; John A Kairalla; Todd A Alonzo
Journal:  JCO Precis Oncol       Date:  2019-10-24

4.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976

5.  Directions for new developments on statistical design and analysis of small population group trials.

Authors:  Ralf-Dieter Hilgers; Kit Roes; Nigel Stallard
Journal:  Orphanet J Rare Dis       Date:  2016-06-14       Impact factor: 4.123

Review 6.  An overview of the impact of rare disease characteristics on research methodology.

Authors:  Danielle Whicher; Sarah Philbin; Naomi Aronson
Journal:  Orphanet J Rare Dis       Date:  2018-01-19       Impact factor: 4.123

7.  Factors Contributing to the Efficacy-Effectiveness Gap in the Case of Orphan Drugs for Metabolic Diseases.

Authors:  Y Schuller; C E M Hollak; C C Gispen-de Wied; V Stoyanova-Beninska; M Biegstraaten
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

Review 8.  Rett Syndrome: Crossing the Threshold to Clinical Translation.

Authors:  David M Katz; Adrian Bird; Monica Coenraads; Steven J Gray; Debashish U Menon; Benjamin D Philpot; Daniel C Tarquinio
Journal:  Trends Neurosci       Date:  2016-02       Impact factor: 13.837

9.  Clinical evidence for orphan medicinal products-a cause for concern?

Authors:  Eline Picavet; David Cassiman; Carla E Hollak; Johan A Maertens; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-10-16       Impact factor: 4.123

10.  In silico study of medical decision-making for rare diseases: heterogeneity of decision-makers in a population improves overall benefit.

Authors:  Juan Wang; Ryo Yamada
Journal:  PeerJ       Date:  2018-09-25       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.